ACHIEVE LIFE SCIENCES, INC. ACHV
We are a late-stage clinical specialty pharmaceutical company with the sole mission to address the global nicotine dependence epidemic through the development and commercialization of cytisinicline. There are an estimated 29 million adults in the United States alone who smoke combustible cigarettes and an estimated 17 million adults in the United States who utilize e-cigarettes. Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. Our primary focus is to address this global epidemic.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | — | — |
| R&D | — | $22.8M | $15.8M | $30.1M | $24.0M | $6.9M | $9.7M | $5.9M | $3.1M | $286.0K |
| SG&A | — | $16.3M | $11.4M | $10.7M | $9.1M | $7.9M | $6.9M | $6.9M | $3.5M | $1.4M |
| Total operating expenses | $54.9M | $39.1M | $27.2M | $40.8M | $33.1M | $14.8M | $16.5M | $12.8M | $6.6M | $1.7M |
| Interest expense | $819.0K | $2.2M | $2.9M | $1.8M | — | — | — | — | — | — |
| Pre-tax income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M | -$14.7M | -$16.4M | -$12.7M | -$13.6M | -$1.7M |
| Income tax | — | — | — | — | — | — | — | — | — | $0 |
| Net income | -$54.6M | -$39.8M | -$29.8M | -$42.4M | -$33.2M | -$14.7M | -$16.4M | -$12.7M | -$10.6M | -$1.2M |
| EPS, basic | -1.25 | -1.24 | -1.50 | -4.00 | -4.08 | -5.42 | — | — | — | — |
| EPS, diluted | -1.25 | -1.24 | -1.50 | -4.00 | -4.08 | -5.42 | -39.76 | -72.29 | -22.07 | -581.25 |
| Shares, diluted (wtd. avg.) | 43.6M | 32.1M | 19.8M | 10.6M | 8.1M | 2.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.9M | $12.8M | $15.5M | $24.8M | $43.0M | $35.9M | $16.7M | $9.5M | $5.3M | $15.0K |
| Short-term investments | $15.5M | $21.6M | — | — | — | — | — | $5.1M | — | $10.2M |
| Receivables | — | — | — | — | — | — | $8.0K | $7.0K | $9.0K | $478.0K |
| Total current assets | $39.9M | $36.5M | $17.0M | $27.3M | $44.6M | $37.0M | $17.3M | $15.5M | $5.9M | $18.0K |
| Property, plant and equipment | $3.0K | $8.0K | $13.0K | $4.0K | $15.0K | $42.0K | $57.0K | $35.0K | $59.0K | $258.0K |
| Goodwill | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M |
| Other intangibles | $751.0K | $974.0K | $1.2M | $1.4M | $1.6M | $1.9M | $2.1M | $2.3M | $2.5M | $2.8M |
| Total assets | $41.8M | $38.6M | $19.4M | $30.0M | $47.5M | $40.3M | $21.1M | $19.1M | $9.9M | $3.8M |
| Accounts payable | — | $1.9M | $618.0K | $1.7M | $841.0K | $332.0K | $859.0K | $144.0K | $213.0K | $95.0K |
| Total current liabilities | $9.1M | $6.7M | $20.8M | $21.6M | $4.5M | $2.9M | $2.9M | $3.3M | $2.0M | $3.1M |
| Total liabilities | $20.3M | $17.7M | $20.8M | $21.7M | $19.5M | $3.0M | $3.0M | $3.3M | $2.0M | $3.2M |
| Retained earnings | -$260.2M | -$205.6M | -$165.8M | -$135.9M | -$93.6M | -$60.4M | -$45.7M | -$25.4M | -$12.7M | -$2.1M |
| Total equity | $21.5M | $20.9M | -$1.4M | $8.3M | $28.0M | $37.3M | $18.1M | $15.8M | $15.8M | $610.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.5M | -$29.8M | -$24.5M | -$37.6M | -$29.4M | -$13.5M | -$15.2M | -$10.6M | -$9.1M | -$202.0K |
| Depreciation and amortisation | — | — | — | — | $27.0K | $32.0K | $31.0K | $60.0K | $59.0K | $188.0K |
| Stock-based compensation | $8.8M | $5.3M | $3.4M | $3.3M | $2.2M | $1.3M | $1.2M | $854.0K | $348.0K | $1.6M |
| Capital expenditure | $3.0K | — | $21.0K | — | — | $17.0K | $53.0K | $46.0K | — | $46.0K |
| Investing cash flow | $6.1M | -$21.6M | -$21.0K | — | — | -$17.0K | $5.0M | -$5.1M | $12.6M | $10.6M |
| Financing cash flow | $51.5M | $48.5M | $15.3M | $19.3M | $36.6M | $32.7M | $17.3M | $19.8M | $2.0M | $150.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000949858-26-000006.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$1.2M | -$10.6M | -$12.7M | -$16.4M | -$14.7M | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |
| TKNO | Alpha Teknova, Inc. | $344.7M | — | 7.4% |